The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

The EMA's human medicines committee has recommended approval for Bavarian Nordic's chikungunya vaccine, which is shaping up to be the first alternative to a rival shot from Valneva. The CHIKV VLP ...

Rival developer Bavarian Nordic recently filed its single-dose CHIKV VLP vaccine candidate for chikungunya in the EU and US, seeking approval for individuals aged 12 and over. Bain Capital has ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

A Phase I trial of Replicate Bioscience’s self-replicating RNA-based vaccine for rabies has elicited an immune ... an immune response comparable to the current standard of care, Bavarian Nordic’s ...

Accordingly, the single-shot vaccine branded as Ixchiq will be indicated in the U.K. for those 18 years and older to prevent chikungunya, a mosquito-borne disease caused by the chikungunya virus.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use in adults. Ixchiq is now the first vaccine approved in the UK to prevent ...